logo

US7767449B1 Methods using modified vaccinia virus

If you want to confirm some technical details before you order,
just need to send a message or e-mail: [email protected].
Then our professional sales staff will contact you within 2 hours.

Vaccinia - Wikiped

Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It has a linear, double-stranded DNA genome approximately 190 kbp in length, and which encodes approximately 250 genes.The dimensions of the virion are roughly 360 × 270 × 250 nm, with a mass of approximately 5–10 fg.. Smallpox was the first disease to be widely prevented by vaccination, due ...

US5514375A - Flavivirus recombinant poxvirus vaccine .

What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from flavivirus, such as Japanese encephalitis virus, yellow fever virus and Dengue virus. In a preferred embodiment, the recombinant poxvirus generates an extracellular particle containing flavivirus E and M proteins capable of inducing neutralizing antibodies ...

Modified Vaccinia Virus Ankara Triggers Type I IFN .

Modified vaccinia virus Ankara (MVA) is an attenuated vaccinia strain with large deletions of the parental genome that render it non-replicative in mammalian cells. MVA is a safe and effective vaccine against both smallpox and monkeypox. MVA has been investigated as a vaccine vector for infectious diseases and cancers.

US5972597A - Methods using modified vaccinia virus .

What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified and genetically modified microorganisms involved as intermediates in such methods; and methods for infecting cells and host animals with ...

US Patent for Methods using modified vaccinia virus Patent .

What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified and genetically modified microorganisms involved as intermediates in such methods; and methods for infecting cells and host animals with ...

US7767449B1 - Methods using modified vaccinia virus .

The present invention relates to modified vaccinia virus, to methods of making and using the same, and to other modified and unmodified microorganisms, and to certain DNA sequences, produced or involved as intermediates in the production of modified vaccinia virus.

US7767449B1 - Methods using modified vaccinia virus .

The present invention relates to modified vaccinia virus, to methods of making and using the same, and to other modified and unmodified microorganisms, and to certain DNA sequences, produced or involved as intermediates in the production of modified vaccinia virus.

US4237224A - Process for producing biologically functional .

US4237224A - Process for producing biologically functional ...

MOLECULAR BIOMARKERS FOR CANCER IMMUNOTHERAPY .

MOLECULAR BIOMARKERS FOR CANCER IMMUNOTHERAPY. Document Type and Number: WIPO Patent Application WO/2016/100975

Methods using modified vaccinia virus - Health Research .

Methods using modified vaccinia virus . United States Patent 5972597 . Abstract: What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified and ...

Modified vaccinia Ankara - Wikiped

Concerns about the safety of the vaccinia virus have been addressed by the development of vectors based on attenuated vaccinia viruses. One of them, the Modified Vaccinia Ankara (MVA') virus, is a highly attenuated strain of vaccinia virus that was developed towards the end of the campaign for the eradication of smallpox by Anton Mayr in

Neutralization Assay Using a Modified Vaccinia Virus Ankara .

Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput ... methods to measure anti-vaccinia virus neutralizing antibodies

Efficiently Editing the Vaccinia Virus Genome by Using the .

TEXT. Since the eradication of smallpox, vaccinia virus (VACV) has been developed as a vector for vaccines against infectious diseases and immunotherapies for cancer (1,– 4), including oncolytic virotherapies (5,– 8).The renewed interest in VACV has driven a number of vaccine and therapeutic candidates to clinical trials, showing especially encouraging results for cancer treatment (5, 7).

WO1994016716A1 - Recombinant virus ... - patents.glgoo.t

WO1994016716A1 - Recombinant virus ... - patents.glgoo.top

Methods using modified vaccinia virus - Patent - Europe P

What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified and genetically modified microorganisms involved as intermediates in such methods; and methods for infecting cells and host animals with ...

Vaccinia Virus - an overview | ScienceDirect Topi

Anette Schneemann, Mark J Young, in Advances in Protein Chemistry, 2003. 2 Vaccinia Virus System. Vaccinia virus is a large double-stranded DNA virus that infects many types of mammalian cells and some invertebrate cells. Its replication cycle is confined to the cytoplasm and can be divided into an early phase and a late phase.

FORMULATIONS FOR NEOPLASIA VACCINES AND METHODS OF .

The present invention relates to neoplasia vaccine or immunogenic composition formulation for the treatment or prevention of neoplasia in a subject and to methods of preparing thereof.

MOLECULAR BIOMARKERS FOR CANCER IMMUNOTHERAPY .

MOLECULAR BIOMARKERS FOR CANCER IMMUNOTHERAPY. Document Type and Number: WIPO Patent Application WO/2016/100975